<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35354288</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0008-7335</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>161</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Season>Spring</Season>
            </PubDate>
          </JournalIssue>
          <Title>Casopis lekaru ceskych</Title>
          <ISOAbbreviation>Cas Lek Cesk</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Current treatment options for monogenic periodic fever syndromes - the role of interleukin 1 inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>3</StartPage>
          <EndPage>10</EndPage>
          <MedlinePgn>3-10</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Monogenic periodic fever syndromes are heterogeneous group of autoinflammatory diseases including distinct syndromes, such as cryopyrin-associated periodic syndrome (CAPS), tumor necrosis factor alpha receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyper IgD syndrome (MKD/HIDS), and familial Mediterranean fever (FMF). Individual diseases differ in pathogenesis, clinical manifestations, and severity. However, cytokines from the interleukin 1 (IL-1) family play a key role in all of them. Inhibition of these cytokines, especially IL-1, thus plays a crucial role in their treatment. At present, we have a wide range of drugs that differ in structure, mechanism of action, efficacy, and spectrum of side effects. The most available are anakinra, canakinumab and rilonacept. Moreover, several clinical trials are currently underway with other very promising drugs, such as gevokizumab, tadekinig alfa or tranilast. In the following review, we provide a new perspective on the efficacy and safety of IL-1 inhibitors that have provided the novel results coming from recently published clinical trials.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Milota</LastName>
            <ForeName>Tomáš</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malcová</LastName>
            <ForeName>Hana</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Střížová</LastName>
            <ForeName>Zuzana</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cebecauerová</LastName>
            <ForeName>Dita</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Horváth</LastName>
            <ForeName>Rudolf</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Sou&amp;#269;asné mo&amp;#382;nosti lé&amp;#269;by monogenních syndrom&amp;#367; periodických hore&amp;#269;ek - úloha inhibitor&amp;#367; interleukinu 1.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Czech Republic</Country>
        <MedlineTA>Cas Lek Cesk</MedlineTA>
        <NlmUniqueID>0004743</NlmUniqueID>
        <ISSNLinking>0008-7335</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000088902">Interleukin Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D056587" MajorTopicYN="Y">Cryopyrin-Associated Periodic Syndromes</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056660" MajorTopicYN="Y">Hereditary Autoinflammatory Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000088902" MajorTopicYN="N">Interleukin Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054078" MajorTopicYN="Y">Mevalonate Kinase Deficiency</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anakinra</Keyword>
        <Keyword MajorTopicYN="N">canakinumab</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="N">interleukin 1</Keyword>
        <Keyword MajorTopicYN="N">monogenic periodic fever syndromes</Keyword>
        <Keyword MajorTopicYN="N">rilonacept</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>5</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35354288</ArticleId>
        <ArticleId IdType="pii">130439</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
